JP2024009978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024009978A5 JP2024009978A5 JP2023178204A JP2023178204A JP2024009978A5 JP 2024009978 A5 JP2024009978 A5 JP 2024009978A5 JP 2023178204 A JP2023178204 A JP 2023178204A JP 2023178204 A JP2023178204 A JP 2023178204A JP 2024009978 A5 JP2024009978 A5 JP 2024009978A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- pregnant
- gbs
- disease
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims 22
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000031942 Late Onset disease Diseases 0.000 claims 4
- 150000004676 glycans Chemical class 0.000 claims 4
- 229920001282 polysaccharide Polymers 0.000 claims 4
- 239000005017 polysaccharide Substances 0.000 claims 4
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 241000193985 Streptococcus agalactiae Species 0.000 claims 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195669A JP2025024038A (ja) | 2015-05-04 | 2024-11-08 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156500P | 2015-05-04 | 2015-05-04 | |
| US62/156,500 | 2015-05-04 | ||
| US201562237813P | 2015-10-06 | 2015-10-06 | |
| US201562237820P | 2015-10-06 | 2015-10-06 | |
| US62/237,820 | 2015-10-06 | ||
| US62/237,813 | 2015-10-06 | ||
| US201662319539P | 2016-04-07 | 2016-04-07 | |
| US62/319,539 | 2016-04-07 | ||
| JP2017557093A JP6948951B2 (ja) | 2015-05-04 | 2016-04-29 | Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
| JP2021152763A JP2022008445A (ja) | 2015-05-04 | 2021-09-21 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021152763A Division JP2022008445A (ja) | 2015-05-04 | 2021-09-21 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195669A Division JP2025024038A (ja) | 2015-05-04 | 2024-11-08 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024009978A JP2024009978A (ja) | 2024-01-23 |
| JP2024009978A5 true JP2024009978A5 (https=) | 2024-10-01 |
| JP7587659B2 JP7587659B2 (ja) | 2024-11-20 |
Family
ID=55967339
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557093A Active JP6948951B2 (ja) | 2015-05-04 | 2016-04-29 | Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
| JP2021152763A Pending JP2022008445A (ja) | 2015-05-04 | 2021-09-21 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
| JP2023178204A Active JP7587659B2 (ja) | 2015-05-04 | 2023-10-16 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
| JP2024195669A Pending JP2025024038A (ja) | 2015-05-04 | 2024-11-08 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557093A Active JP6948951B2 (ja) | 2015-05-04 | 2016-04-29 | Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
| JP2021152763A Pending JP2022008445A (ja) | 2015-05-04 | 2021-09-21 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195669A Pending JP2025024038A (ja) | 2015-05-04 | 2024-11-08 | Ｂ群レンサ球菌多糖－タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10226525B2 (https=) |
| EP (1) | EP3292146A1 (https=) |
| JP (4) | JP6948951B2 (https=) |
| KR (2) | KR102045663B1 (https=) |
| CN (2) | CN114010775B (https=) |
| AU (2) | AU2016258284C1 (https=) |
| CA (1) | CA2928602A1 (https=) |
| CO (1) | CO2017011245A2 (https=) |
| IL (2) | IL297740B2 (https=) |
| MX (1) | MX368897B (https=) |
| MY (1) | MY182282A (https=) |
| NZ (1) | NZ736238A (https=) |
| PE (2) | PE20220774A1 (https=) |
| PH (1) | PH12017501898A1 (https=) |
| RU (1) | RU2692923C2 (https=) |
| SA (1) | SA517390274B1 (https=) |
| SG (2) | SG10202101887WA (https=) |
| TW (2) | TWI718144B (https=) |
| WO (1) | WO2016178123A1 (https=) |
| ZA (1) | ZA201807203B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| BR112016015835B1 (pt) * | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| MY182282A (en) * | 2015-05-04 | 2021-01-18 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| US10751402B2 (en) * | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN108144052A (zh) * | 2016-12-02 | 2018-06-12 | 武汉博沃生物科技有限公司 | 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3568157A4 (en) * | 2017-01-13 | 2021-01-06 | National Research Council of Canada | PROCESS FOR THE OPTIMIZATION OF PEPTIDIC IMMUNO-EPITOPE BY GLYCOSYLATION, ASSOCIATED OPTIMIZED PEPTIDE AND ITS USE FOR CONJUGATE VACCINES |
| EP4656208A3 (en) | 2017-01-31 | 2026-03-04 | Merck Sharp & Dohme LLC | Methods for making polysaccharide-protein conjugates |
| JP7680185B2 (ja) | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強 |
| MX2019009869A (es) * | 2017-02-24 | 2019-10-02 | Merck Sharp & Dohme | Formulaciones de vacunas de conjugado de neumococos. |
| EP3638301A1 (en) | 2017-06-16 | 2020-04-22 | GlaxoSmithKline Biologicals S.A. | Method of treatment |
| CN110996992A (zh) * | 2017-08-16 | 2020-04-10 | 默沙东公司 | 肺炎球菌缀合物疫苗制剂 |
| MX394768B (es) | 2017-09-07 | 2025-03-21 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina. |
| MX394767B (es) | 2017-09-07 | 2025-03-24 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. |
| MX2020002558A (es) * | 2017-09-07 | 2020-07-13 | Merck Sharp & Dohme | Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora. |
| ES3058336T3 (es) | 2017-12-06 | 2026-03-10 | Merck Sharp & Dohme Llc | Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos |
| EP3787673A4 (en) | 2018-04-30 | 2022-04-27 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| US12144855B2 (en) | 2018-04-30 | 2024-11-19 | Merck Sharp & Dohme Llc | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| EP3788143B1 (en) * | 2018-04-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| KR102120830B1 (ko) * | 2018-09-20 | 2020-06-09 | 고려대학교산학협력단 | 신규 b군 연쇄상구균 혈청형 균주 및 이를 포함하는 면역원성 조성물 |
| CR20210333A (es) | 2018-12-19 | 2021-08-18 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso |
| JP7555929B2 (ja) * | 2018-12-24 | 2024-09-25 | 遠大賽威信生命科学（南京）有限公司 | Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途 |
| BR112021022429A2 (pt) * | 2019-05-10 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Produção de conjugados |
| EP3777884A1 (en) * | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| WO2021059181A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CN112741901B (zh) * | 2019-10-31 | 2024-05-10 | 北京科兴中维生物技术有限公司 | 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法 |
| US12533418B2 (en) | 2019-11-22 | 2026-01-27 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
| WO2021250625A2 (en) | 2020-06-12 | 2021-12-16 | Glaxosmithkline Biologicals Sa | Gbs ferritin nanoparticles |
| MX2022015860A (es) | 2020-06-12 | 2023-01-24 | Glaxosmithkline Biologicals Sa | Inmunizacion bacteriana que utiliza una vacuna con nanoparticulas. |
| CN114073761B (zh) * | 2020-08-11 | 2023-11-14 | 山东大学 | 一种寡糖缀合物及其作为预防v型b族链球菌感染糖疫苗的应用 |
| KR20230056727A (ko) * | 2020-08-26 | 2023-04-27 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2022103639A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| CN112939164B (zh) * | 2021-03-15 | 2022-05-24 | 广西大学 | 海产养殖水体的消毒方法 |
| JP2024521847A (ja) * | 2021-05-28 | 2024-06-04 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用 |
| CN113480622A (zh) * | 2021-08-05 | 2021-10-08 | 江苏坤力生物制药有限责任公司 | 一种重组肺炎球菌溶血素制备及纯化的方法 |
| CN113651730A (zh) * | 2021-08-20 | 2021-11-16 | 宿迁盛瑞新材料有限公司 | 一种双（十八烷基）羟胺的制备方法 |
| CN115960962A (zh) * | 2021-10-09 | 2023-04-14 | 江苏金斯瑞蓬勃生物科技有限公司 | 一种用于加强慢病毒载体稳定性的保护剂及其用途 |
| CN113621089B (zh) * | 2021-10-11 | 2021-12-17 | 山东洁壹选生物科技有限公司 | 一种海藻多糖提取物的制备方法和应用 |
| CN114015622A (zh) * | 2021-12-14 | 2022-02-08 | 塔里木大学 | 无乳链球菌培养基及其制备方法 |
| WO2023111826A1 (en) | 2021-12-14 | 2023-06-22 | Glaxosmithkline Biologicals Sa | Bacterial immunization using qbeta hairpin nanoparticle constructs |
| CN118453847A (zh) * | 2024-05-22 | 2024-08-09 | 中国人民解放军军事科学院军事医学研究院 | Sip蛋白在制备荚膜多糖结合疫苗中的应用、及包含Sip蛋白的偶联物及其制备方法和应用 |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360897A (en) | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FI940700A7 (fi) * | 1991-08-16 | 1994-02-15 | Merck & Co Inc | Prosessi lipidiä sisältävän bakteerisen kapsulaarisen polysakkaridin k onvertoimiseksi lipidivapaaksi polysakkaridiksi |
| US5371197A (en) * | 1991-09-24 | 1994-12-06 | Merck & Co., Inc. | Protein-dimeric polysaccharide conjugate vaccine |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| ES2204900T3 (es) | 1992-02-11 | 2004-05-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Estructura inmuinogena de doble vector. |
| EP0667787B1 (en) * | 1992-09-24 | 2001-07-18 | Brigham And Women's Hospital | Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines |
| ZA937034B (en) * | 1992-09-24 | 1995-06-23 | Brigham & Womens Hospital | Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines |
| ATE280235T1 (de) | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| WO1995008348A1 (en) | 1993-09-22 | 1995-03-30 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| BE1008978A5 (fr) | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
| NZ304715A (en) | 1995-03-22 | 1999-07-29 | Jackson H M Found Military Med | Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten |
| GB9622159D0 (en) | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
| GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US20010051364A1 (en) * | 1997-12-23 | 2001-12-13 | Francis Michon | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines |
| KR100757630B1 (ko) * | 1997-12-23 | 2007-09-10 | 박스터 헬쓰케어 에스.에이. | 신규한 추출 및 단리 방법으로 수득되는 세균성 캡슐형 다당류 |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
| US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
| RU2413520C2 (ru) | 2000-06-08 | 2011-03-10 | Интерселл Аг | Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| US7332174B2 (en) | 2001-06-07 | 2008-02-19 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| AU2002346249B2 (en) | 2001-06-07 | 2007-03-15 | The Regents Of The University Of Colorado | Mutant Forms of Cholera Holotoxin as an Adjuvant |
| TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| WO2004011027A1 (en) * | 2002-07-30 | 2004-02-05 | Baxter International Inc. | Chimeric multivalent polysaccharide conjugate vaccines |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| US20060251675A1 (en) | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| EP1638601B1 (en) * | 2003-06-23 | 2008-11-19 | Baxter International Inc. | Carrier proteins for vaccines |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| GB0411387D0 (en) * | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
| GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN101155833B (zh) | 2005-04-08 | 2011-04-20 | 惠氏公司 | 通过pH操作将污染物与肺炎链球菌多糖分离 |
| EP3311836A1 (en) | 2005-04-08 | 2018-04-25 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| GB0522303D0 (en) | 2005-11-01 | 2005-12-07 | Chiron Srl | Culture method |
| KR101515078B1 (ko) | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| DK2074221T3 (da) | 2006-10-10 | 2010-09-06 | Wyeth Llc | Forbedrede fremgangsmåder til separation af streptococcus pneumoniae type 3 polysakkarider |
| CN101663327B (zh) | 2007-03-23 | 2014-05-07 | 惠氏公司 | 产生肺炎链球菌(streptococcus pneumoniae)荚膜多糖的缩短的纯化方法 |
| CA2690708A1 (en) * | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccine |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| RU2011140357A (ru) | 2009-03-05 | 2013-04-10 | Интердиджитал Пэйтент Холдингз, Инк. | Способ и устройство для проверки и подтверждения целостности h(e)nb |
| SG10201406432RA (en) * | 2009-06-22 | 2014-11-27 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| WO2011080570A2 (en) | 2009-12-29 | 2011-07-07 | Micro Labs Limited | Extended release pharmaceutical composition comprising linezolid and process for preparing the same |
| JP2013538211A (ja) * | 2010-08-23 | 2013-10-10 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗原に対する免疫反応を誘発する標的マルチエピトープ剤形 |
| GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| US9120848B2 (en) | 2010-09-23 | 2015-09-01 | Harvey Kaplan | Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines |
| WO2012061400A2 (en) | 2010-11-01 | 2012-05-10 | University Of Maryland, Baltimore | Method for reduction of free polysaccharide in polysaccharide-protein vaccines reactions using ion-exchange matrices |
| GB201121301D0 (en) * | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| DK2885007T3 (en) * | 2012-08-16 | 2018-12-03 | Pfizer | Methods for glycoconjugation and compositions |
| RU2606022C2 (ru) | 2012-09-07 | 2017-01-10 | Ск Кемикалс Ко., Лтд. | Способ получения капсульного полисахарида с пневмококковым серотипом |
| TR201808684T4 (tr) | 2012-10-02 | 2018-07-23 | Glaxosmithkline Biologicals Sa | Lineer olmayan sakarit konjügatları. |
| RU2015106791A (ru) * | 2012-10-03 | 2016-11-20 | Глэксосмитиклайн Байолоджикалз Са | Иммуногенные композиции |
| KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| JP6502262B2 (ja) * | 2012-12-20 | 2019-04-17 | ファイザー・インク | 糖複合化方法 |
| WO2015084867A1 (en) * | 2013-12-02 | 2015-06-11 | Brandeis University | Multivalent glycopeptides that tightly bind to target proteins |
| PL3096786T3 (pl) * | 2014-01-21 | 2021-11-08 | Pfizer Inc. | Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty |
| CN110859957B (zh) * | 2014-01-21 | 2024-04-12 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| ES2701169T3 (es) * | 2014-02-14 | 2019-02-21 | Pfizer | Conjugados glucoproteicos inmunogénicos |
| BE1022780B1 (fr) * | 2014-05-07 | 2016-09-02 | Glaxosmithkline Biologicals S.A. | Purification des polysaccharides secretes par s. agalactiae |
| TWI583284B (zh) * | 2015-02-06 | 2017-05-11 | 鴻海精密工業股份有限公司 | 保護殼 |
| MY182282A (en) * | 2015-05-04 | 2021-01-18 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| EA201792470A1 (ru) | 2015-06-08 | 2018-10-31 | Серум Инститьют Оф Индия Прайват Лтд. | Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины |
| NZ752348A (en) | 2016-09-30 | 2022-11-25 | Biological E Ltd | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| US10751402B2 (en) * | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11739356B2 (en) * | 2017-05-05 | 2023-08-29 | Serum Institute Of India Private Limited | Method for removal of impurities from bacterial capsular polysaccharide based preparations |
-
2016
- 2016-04-29 MY MYPI2017704078A patent/MY182282A/en unknown
- 2016-04-29 RU RU2017136859A patent/RU2692923C2/ru active
- 2016-04-29 SG SG10202101887WA patent/SG10202101887WA/en unknown
- 2016-04-29 PE PE2022000475A patent/PE20220774A1/es unknown
- 2016-04-29 CN CN202111336096.5A patent/CN114010775B/zh active Active
- 2016-04-29 SG SG11201708242YA patent/SG11201708242YA/en unknown
- 2016-04-29 AU AU2016258284A patent/AU2016258284C1/en active Active
- 2016-04-29 PE PE2017002368A patent/PE20180172A1/es unknown
- 2016-04-29 CN CN201680025709.4A patent/CN107624070A/zh active Pending
- 2016-04-29 KR KR1020177034520A patent/KR102045663B1/ko active Active
- 2016-04-29 WO PCT/IB2016/052455 patent/WO2016178123A1/en not_active Ceased
- 2016-04-29 MX MX2017014127A patent/MX368897B/es active IP Right Grant
- 2016-04-29 JP JP2017557093A patent/JP6948951B2/ja active Active
- 2016-04-29 IL IL297740A patent/IL297740B2/en unknown
- 2016-04-29 EP EP16722381.7A patent/EP3292146A1/en active Pending
- 2016-04-29 TW TW105113585A patent/TWI718144B/zh active
- 2016-04-29 IL IL255106A patent/IL255106B2/en unknown
- 2016-04-29 NZ NZ736238A patent/NZ736238A/en unknown
- 2016-04-29 TW TW110103304A patent/TWI807252B/zh active
- 2016-04-29 KR KR1020197033079A patent/KR102143534B1/ko active Active
- 2016-05-02 CA CA2928602A patent/CA2928602A1/en active Pending
- 2016-05-03 US US15/144,884 patent/US10226525B2/en active Active
-
2017
- 2017-10-18 PH PH12017501898A patent/PH12017501898A1/en unknown
- 2017-11-01 CO CONC2017/0011245A patent/CO2017011245A2/es unknown
- 2017-11-02 SA SA517390274A patent/SA517390274B1/ar unknown
-
2018
- 2018-10-29 ZA ZA2018/07203A patent/ZA201807203B/en unknown
-
2019
- 2019-01-11 US US16/245,378 patent/US10946086B2/en active Active
- 2019-04-17 AU AU2019202680A patent/AU2019202680B2/en active Active
-
2021
- 2021-01-28 US US17/161,119 patent/US20210145957A1/en not_active Abandoned
- 2021-09-21 JP JP2021152763A patent/JP2022008445A/ja active Pending
-
2022
- 2022-12-01 US US18/060,779 patent/US20230346903A1/en active Pending
-
2023
- 2023-10-16 JP JP2023178204A patent/JP7587659B2/ja active Active
-
2024
- 2024-11-08 JP JP2024195669A patent/JP2025024038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024009978A5 (https=) | ||
| JP7268125B2 (ja) | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 | |
| CN108348592B (zh) | 疫苗 | |
| JP5615323B2 (ja) | 肺炎球菌多糖類コンジュゲートワクチン | |
| JP5848790B2 (ja) | 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン | |
| JP2021105036A (ja) | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート | |
| JP2007507487A5 (https=) | ||
| RU2012138368A (ru) | 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком | |
| JP2019526621A5 (https=) | ||
| JP2017504661A5 (https=) | ||
| JP2011042693A5 (https=) | ||
| JP2019526620A5 (https=) | ||
| JP2008526939A5 (https=) | ||
| JP2022130637A5 (https=) | ||
| RU2015106791A (ru) | Иммуногенные композиции | |
| JP2025029014A5 (https=) | ||
| JP2019142898A (ja) | 治療方法 | |
| Chang et al. | Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine | |
| EP3638301A1 (en) | Method of treatment | |
| NZ774978B2 (en) | Group B streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| NZ774978A (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| ZA200107638B (en) | Vaccine. | |
| Edwards et al. | Vaccines against group B Streptococcus | |
| US20220387614A1 (en) | Dosage and administration of a bacterial saccharide glycoconjugate vaccine | |
| Russell et al. | Recent advances in pneumococcal vaccination of children |